
    
      This is a phase II, multi-center, single-arm, global study of MEDI4736 monotherapy in
      patients with PD-L1 positive recurrent or metastatic Squamous Cell Carcinoma of the Head and
      Neck (SCCHN), who have progressed during or after treatment with only 1 systemic palliative
      regimen for recurrent or metastatic disease that must have contained a platinum agent.
    
  